1. In this randomized controlled trial, in patients diagnosed with migraine, it was found that administration of a monoclonal antibody against pituitary adenylate cyclase-activating polypeptide (PACAP), Lu AG09222, was associated with a reduction in migraines frequency. 2. The Lu AG09222 group experienced a higher incidence of adverse events compared to the placebo group, though no […]
The post Infusion with a monoclonal antibody decreases migraine frequency first appeared on Physician’s Weekly.
